Novavax (NVAX) Competitor Comparison
We are evaluating the key criteria listed to compare Novavax (NVAX) against its competitors in the Biotechnology industry.
Market Capitalization
152 / 368Gross Profits
256 / 278Total Revenue
17 / 300EBITDA
327 / 337Free Cashflow
10 / 352Quick Ratio
342 / 357Earnings per Share
238 / 359Dividend yield
0 / 6Total Cash
44 / 358Performance 3 years
331 / 368Performance 5 years
80 / 368Performance 10 years
250 / 368Linearity 3 years
312 / 368Linearity 5 years
20 / 368Linearity 10 years
148 / 368Total Rank
6 / 368Dividend Rank
219 / 368Valuation Rank
164 / 368Piotroski Rank
22 / 368Muliplier Rank
58 / 368Earnings per Share - NVAX ranking 238 / 359
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.